Science Explorer Back to mapMap
Discussion
Topic · Cutaneous lymphoproliferative disorders research

Most cited papers in Cutaneous lymphoproliferative disorders research

Cutaneous lymphoproliferative disorders research

What are the most cited papers in Cutaneous lymphoproliferative disorders research?

The most cited paper in Cutaneous lymphoproliferative disorders research is "The 2016 revision of the World Health Organization classification of lymphoid neoplasms" (Steven H. Swerdlow, Elı́as Campo, Stefano Aldo Pileri et al., 2016), with 7,935 citations. Next come "Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma" (6,098) and "Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma" (5,108).

Showing 50 of 100 papers. Every paper with more than 509 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 The 2016 revision of the World Health Organization classification of lymphoid neoplasms Steven H. Swerdlow, Elı́as Campo, Stefano Aldo Pileri et al. · Blood Open access 15 Mar 2016 7,935
2 Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma Sattva Swarup Neelapu et al. · New England Journal of Medicine Open access 10 Dec 2017 6,098
3 Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma Bernard J. Poiesz, Francis W. Ruscetti, Adi F. Gazdar et al. · Proceedings of the National Academy of Sciences Open access Dec 1980 5,108
4 WHO-EORTC classification for cutaneous lymphomas Rein Willemze · Blood Open access 3 Feb 2005 3,826
5 T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Daniel W Lee, James N. Kochenderfer, Maryalice Stetler‐Stevenson et al. · The Lancet Open access 13 Oct 2014 2,968
6 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Peter Joseph McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology Aug 1998 2,774
7 Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study Jeremy S Abramson et al. · The Lancet Sep 2020 2,422
8 Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma Roland P. H. Schmitz et al. · New England Journal of Medicine Open access 11 Apr 2018 2,325
9 High burden and pervasive positive selection of somatic mutations in normal human skin Iñigo Martincorena, Amit Roshan, Moritz Gerstung et al. · Science Open access 22 May 2015 1,880
10 KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma Michael Wang et al. · New England Journal of Medicine Open access Apr 2020 1,874
11 Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma Noopur S Raje et al. · New England Journal of Medicine Open access May 2019 1,775
12 Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma Michael Wang et al. · New England Journal of Medicine Open access 19 Jun 2013 1,710
13 Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma Mark E. Dudley et al. · Journal of Clinical Oncology Open access 30 Mar 2005 1,640
14 Follicular Lymphoma International Prognostic Index P. Solal-Celigny · Blood Open access 11 May 2004 1,544
15 Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · The Lancet 19 Feb 2013 1,515
16 Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte Pierre Feugier, Ambro van Hoof, Catherine Sebban et al. · Journal of Clinical Oncology 2 May 2005 1,510
17 Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) Elise A. Olsen et al. · Blood 31 May 2007 1,437
18 The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas Rein Willemze, Lorenzo Cerroni, Werner Kempf et al. · Blood Open access 11 Jan 2019 1,417
19 FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma Bhupinder Singh Mann, John R. Johnson, Martin H. Cohen et al. · The Oncologist Oct 2007 1,377
20 Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas Anas Younes, Nancy L. Bartlett, John Paul Leonard et al. · New England Journal of Medicine Open access 3 Nov 2010 1,371
21 EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Rein Willemze, H. Kerl, Wolfram Sterry et al. · PubMed Jul 1997 1,291
22 The IL-1-Like Cytokine IL-33 Is Constitutively Expressed in the Nucleus of Endothelial Cells and Epithelial Cells In Vivo: A Novel ‘Alarmin’? Christine Moussion, Nathalie Ortéga, Jean‐Philippe Girard · PLoS ONE Open access 3 Oct 2008 1,191
23 2016 US lymphoid malignancy statistics by World Health Organization subtypes Lauren R. Teras, Carol E. Desantis, James R. Cerhan et al. · CA A Cancer Journal for Clinicians Open access 12 Sep 2016 1,148
24 Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial Norbert Schmitz, Beate Pfistner, Michael Sextro et al. · The Lancet Jun 2002 1,143
25 Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Madeleine Duvic, Rakshandra Talpur, Xiao Ni et al. · Blood Open access 7 Sep 2006 1,143
26 Nonmelanoma skin cancer in the United States: Incidence Dena L. Miller, Martin A. Weinstock · Journal of the American Academy of Dermatology May 1994 1,120
27 Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial Gilles Salles et al. · The Lancet 21 Dec 2010 1,081
28 Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma Elise A. Olsen, Youn H. Kim, Timothy Michael Kuzel et al. · Journal of Clinical Oncology 18 Jun 2007 1,057
29 A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling Michael Hummel et al. · New England Journal of Medicine Open access 7 Jun 2006 1,015
30 Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study Barbara Pro, Ranjana H. Advani, Pauline Brice et al. · Journal of Clinical Oncology Open access 21 May 2012 1,001
31 Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma Nabil M. Ahmed et al. · Journal of Clinical Oncology Open access 23 Mar 2015 1,001
32 Treatment of a first patient with FLASH-radiotherapy Jean Bourhis, Wendy Jeanneret Sozzi, Patrik Gonçalves Jorge et al. · Radiotherapy and Oncology 11 Jul 2019 959
33 CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features Harald Stein, Hans‐Dieter Foss, Horst Dürkop et al. · Blood Dec 2000 955
34 Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes Izidore S. Lossos, Debra Katherine Czerwinski, Ash A. Alizadeh et al. · New England Journal of Medicine 28 Apr 2004 936
35 Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma Hervé Tilly et al. · New England Journal of Medicine Open access 14 Dec 2021 923
36 ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project Kerry J. J. Savage, Nancy L. Harris, Julie Marie Vose et al. · Blood Open access 2 Apr 2008 865
37 Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal Nita Agar, Emma Wedgeworth, Siobhan L. Crichton et al. · Journal of Clinical Oncology 21 Sep 2010 854
38 Cutaneous squamous cell carcinoma Syril Keena T. Que, Fiona O’Reilly Zwald, Chrysalyne Delling Schmults · Journal of the American Academy of Dermatology 12 Jan 2018 821
39 Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma Jesús F. San Miguel et al. · New England Journal of Medicine Open access 5 Jun 2023 814
40 Obinutuzumab for the First-Line Treatment of Follicular Lymphoma Robert E Marcus, Andrew John Davies, Kiyoshi Ando et al. · New England Journal of Medicine Open access 4 Oct 2017 812
41 Mechanisms of cutaneous toxicities to EGFR inhibitors Mario E. Lacouture · Nature reviews. Cancer Review 22 Sep 2006 789
42 Primary and secondary cutaneous CD30+lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment Marcel W. Bekkenk, Françoise A. M. J. Geelen, Pieter C. van Voorst Vader et al. · Blood 15 Jun 2000 787
43 Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Laurie Helen Sehn, Alex Francisco Herrera, Christopher R. Flowers et al. · Journal of Clinical Oncology Open access 6 Nov 2019 785
44 Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia Bernard J. Poiesz, Francis W. Ruscetti, Marvin S. Reitz et al. · Nature Nov 1981 762
45 Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project Massimo Federico, Monica Bellei, Luigi Marcheselli et al. · Journal of Clinical Oncology Open access 3 Aug 2009 757
46 Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Michael John Dickinson et al. · New England Journal of Medicine Open access 11 Dec 2022 753
47 Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial Craig H. Moskowitz, Auayporn P. Nademanee, Tamás Masszi et al. · The Lancet Open access 28 Mar 2015 741
48 Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Steven M. Horwitz et al. · The Lancet Open access169 authors 3 Dec 2018 739
49 Guidelines of care for the management of primary cutaneous melanoma Susan M. Swetter, Hensin Tsao, Christopher Keram Bichakjian et al. · Journal of the American Academy of Dermatology Nov 2018 735
50 Cellular Origin of Human B-Cell Lymphomas Ralf Küppers, Ulf Klein, Martin‐Leo Hansmann et al. · New England Journal of Medicine 11 Nov 1999 717

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.